Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
A clinician I spoke with mentioned a patient who, after starting semaglutide for weight loss, noticed his nightly whiskey craving vanished. He also woke at 3 a.m. with restless legs and saw his lean mass dip on a DEXA scan. That tension, between therapeutic promise and physiological cost, sits at the center of a new Department of Veterans Affairs trial.
The study, launched in 2024 and backed by the VA, tests semaglutide for alcohol use disorder. It tracks drinking reduction, but also muscle composition and sleep architecture. Researchers added a second compound: tesamorelin, a growth hormone-releasing hormone analog. The goal is to see if tesamorelin can blunt semaglutide's catabolic drag on lean tissue while improving sleep fragmentation. The protocol reflects a growing awareness that GLP-1 receptor agonists reshape more than appetite.
Why a VA Trial for Alcohol and GLP-1s?
Semaglutide's effect on alcohol intake surfaced in preclinical work and patient anecdotes. A 2023 review in Physiology & Behavior by Klausen and colleagues cataloged rodent studies showing GLP-1 agonists cut ethanol consumption by 30–50%. Human data remain sparse. A 2022 case series in Diabetes Care described three patients who spontaneously reduced heavy drinking on semaglutide. The VA, treating high rates of comorbid obesity and alcohol use disorder, saw a natural intersection.
The trial enrolls veterans with problem drinking and a BMI over 30. Participants receive weekly semaglutide injections titrated to 1.0 mg, plus daily tesamorelin or placebo. Primary endpoints include drinks per day and heavy drinking days. Secondary endpoints measure lean body mass via DEXA, sleep efficiency via actigraphy, and IGF-1 levels. The design borrows from earlier work on Tirzepatide and Hexarelin stacks for lean mass preservation, where growth hormone secretagogues offset muscle loss during rapid weight reduction.
The Muscle Problem in GLP-1 Weight Loss
Rapid weight loss with GLP-1 drugs often strips lean mass. A 2021 analysis of semaglutide STEP trials in New England Journal of Medicine found that roughly 40% of lost weight came from fat-free mass. That proportion worries clinicians. Skeletal muscle regulates glucose disposal, metabolic rate, and physical function. Losing it can trigger a metabolic slowdown that undermines long-term weight maintenance.
Tesamorelin, FDA-approved for HIV-associated lipodystrophy, increases pulsatile growth hormone secretion. It raises IGF-1 and has been shown to reduce visceral fat while preserving lean mass. In a 2020 paper published in Peptides, Chang and colleagues found that tesamorelin co-administration with a GLP-1 agonist in mice attenuated muscle protein breakdown markers. The VA trial extends that logic to humans, testing whether tesamorelin can shift the body composition ratio during semaglutide therapy.
Other compounds are being explored for similar reasons. Hexarelin, a growth hormone-releasing peptide, shows strong anabolic effects but carries higher cortisol and prolactin spikes. MOTS-c, a mitochondrial-derived peptide, improved muscle insulin sensitivity in a 2019 Cell Metabolism study by Lee et al. AOD-9604, a fragment of human growth hormone, targets fat oxidation without the full hormonal cascade. None have the regulatory track record of tesamorelin, which is why the VA chose it for a safety-first population.
Sleep Architecture and GLP-1 Agonists
Sleep disruption on semaglutide is underrecognized. Clinical trial adverse event reports list insomnia at 1–3%, but patient forums tell a different story. A 2023 survey in Sleep Medicine by Patel and colleagues found that 22% of GLP-1 users reported new-onset sleep maintenance insomnia. The mechanism may involve altered glucose nadirs, increased heart rate, or direct central nervous system effects. Semaglutide crosses the blood-brain barrier and binds receptors in the hypothalamus, a region that governs sleep-wake cycles.
Tesamorelin's sleep effects are indirect but documented. Growth hormone secretion peaks during slow-wave sleep. In a 2018 study in Psychoneuroendocrinology, Vgontzas and colleagues showed that exogenous growth hormone-releasing hormone improved sleep continuity in older adults. The VA trial will track sleep via wrist actigraphy and sleep diaries, looking for changes in total sleep time and wake after sleep onset. If tesamorelin deepens sleep, it could address a compliance-killing side effect.
Research Consensus: Early, Fragmented, but Directional
The literature on GLP-1s and alcohol use is nascent but consistent. A 2023 systematic review in JAMA Psychiatry by Hendershot and colleagues pooled six observational studies and found a 40–60% reduction in alcohol consumption among GLP-1 users. Mechanistic studies point to GLP-1 receptors in the nucleus accumbens and ventral tegmental area, where they modulate dopamine signaling. Semaglutide appears to blunt the rewarding properties of alcohol, similar to naltrexone but through a different pathway.
On the muscle-preservation side, the evidence is thinner. Most data come from obesity trials where lean mass loss was a secondary endpoint. The STEP 1 trial reported a 9.6 kg fat mass loss and 5.3 kg lean mass loss at 68 weeks. No approved adjunct exists to shift that ratio. Tirzepatide shows a slightly better lean mass profile in head-to-head comparisons, possibly due to dual incretin agonism, but the difference is modest. The VA trial is the first to prospectively test a muscle-sparing strategy in a psychiatric indication.
Active Research and Where the Gaps Sit
Beyond the VA, at least three other trials are examining GLP-1s for substance use disorders. A 2024 study at the University of North Carolina is testing semaglutide for cocaine use. A Danish trial is looking at alcohol and nicotine. None include a muscle or sleep adjunct. That makes the VA protocol unique. It also highlights a gap: most addiction researchers are not trained in body composition assessment, and most obesity researchers do not study addiction endpoints. The VA trial bridges that divide.
Gaps remain in understanding dose-response for alcohol effects. Semaglutide's anti-craving signal appears at 0.5 mg weekly, below the 2.4 mg obesity dose. Whether higher doses yield greater alcohol suppression or more side effects is unknown. Tesamorelin's optimal dose for muscle preservation in this context is also unclear. The VA is using 2 mg daily, the approved dose for lipodystrophy. But growth hormone secretagogues have a narrow therapeutic window. Too much can cause insulin resistance and joint pain.
Another gap is durability. If semaglutide reduces drinking for six months, what happens when it is stopped? A 2022 paper in Addiction Biology by Jerlhag and colleagues found that alcohol intake rebounded in rodents after GLP-1 agonist cessation. Human data are absent. The VA trial includes a 12-week follow-up off treatment, which will provide the first controlled data on relapse after GLP-1 discontinuation. That matters for chronic disease management, where indefinite treatment is often assumed but rarely tested.
Safety monitoring is critical. Tesamorelin can elevate IGF-1 above age-adjusted norms. Long-term elevation is linked to cancer risk, though short-term data are reassuring. The VA will track IGF-1, glucose, and HbA1c monthly. Semaglutide's known gastrointestinal side effects may be compounded by tesamorelin's known arthralgias. A 2021 post-hoc analysis of tesamorelin trials in AIDS by Falutz and colleagues found no increase in serious adverse events over 52 weeks, but the population was younger and leaner than the VA cohort.
Market and Regulatory Context
Semaglutide is already in short supply. Adding an alcohol use disorder indication would strain manufacturing. Compounded versions fill gaps but operate in a regulatory gray zone. The FDA's 2024 decision to allow compounding during shortages has created a parallel market where peptides like tesamorelin, hexarelin, and AOD-9604 are sold alongside GLP-1s. Semaglutide versus tirzepatide prescribing patterns may shift if one shows superior alcohol effects. Tirzepatide's dual GIP/GLP-1 agonism could theoretically offer stronger dopamine modulation, but no head-to-head alcohol trial exists.
Cost is another layer. Tesamorelin costs roughly $6,000 per month without insurance. Semaglutide for weight loss is $1,300. A combined protocol would exceed $7,000 monthly. The VA can negotiate, but private payers will resist. If the trial shows clear benefit, it could justify a premium indication. If not, the muscle and sleep benefits may remain niche.
The VA trial is scheduled to complete enrollment in 2025, with results in 2026. It represents a pivot point. GLP-1 drugs are no longer just metabolic tools. They are neuropsychiatric probes. Adding peptides like tesamorelin to manage their collateral effects could define the next phase of peptide therapeutics. The question is whether the data will support a new standard of care or simply add another layer of complexity to an already crowded field.